Summary: According to estimates, about 300 million people have Chronic Obstructive Pulmonary Disease (COPD), making it the most common chronic respiratory disease and the third cause of death worldwide. The mainstay of COPD therapy is bronchodilators, but in some patients an inhaled corticosteroid (ICS) is indicated. Some COPD patients may require intensive treatment involving a combination of inhaled ICS with a long-acting beta2-receptor agonist (LABA) and a long-acting muscarinic receptor antagonist (LAMA). This article presents the results of clinical and "real world" studies on the efficacy of three-component therapy with a formulation containing ICS-beclometasone, and -formoterol and LAMA-glycopyrronium in a single inhaler.